India's Sun Pharma beats Q2 profit view on higher demand for specialty drugs
By Rishika Sadam and Kashish Tandon (Reuters) -Sun Pharmaceuticals, India's largest drugmaker by revenue, reported second-quarter profit above analysts' estimates on Monday, aided by higher demand for its specialty drugs that are used to treat uncommon medical conditions.
Sun Pharma's Q2 Profit Surges, Plans Strategic Expansion
Sun Pharmaceutical Industries has reported a notable 28% increase in its consolidated net profit, amounting to Rs 3,040 crore for the September quarter. This rise in profit underscores the company's growth trajectory and strategic commercial agreements to expand its specialty product offerings.
Sun Pharma Q2 profit rises 28% to ₹3,040 cr
Net profit of drugmaker Sun Pharmaceutical Industries rose 28% year-on-year to ₹3,040 crore for the quarter ended Sepember compared with ₹1,375 crore in the corresponding period last fiscal. The company’s revenue from operations increased 9% year-on-year to ₹13,291 crore for the second quarter compared with ₹12,192 crore in the year-ago period.
India's Sun Pharma beats Q2 profit estimates on strong sales
Sun Pharmaceuticals, India's largest drugmaker by revenue, reported second-quarter profit above analysts' estimates on Monday, aided by strong sales of its specialty drugs that are used to treat uncommon medical conditions.
Sun Pharma's Profits Soar with Strategic Expansion
Sun Pharmaceutical Industries reported a 28% rise in net profit, reaching Rs 3,040 crore for the September quarter, driven by strong sales in India and the US. Notably, the company expanded its specialty pipeline and is leveraging its cash position to enhance its product lineup.
Sun Pharma profit up 28% on higher sales
Sun Pharma reported a 28% increase in consolidated net profit for the second quarter ended September, at Rs 3,040 crore, with sales up by 9% to Rs 13,291 crore. The performance was buoyed by robust sales in its main markets,
Sun Pharma Q2 Results: Net profit rises 28% YoY at ₹3,040.16 crore
Sun Pharmaceutical Industries Ltd on Monday reported an 28% year-on-year rise in its consolidated net profit for the fiscal's second quarter ended September (Q2FY24) to ₹3,040.16 crore. The company had reported a profit of ₹23,
Sun Pharma shines in US, home glow to help company beat industry show
The India business, accounting for a third of the company's total revenues, grew at 11%. This is a volume-led growth aided by ...
ndtvprofit20m
Sun Pharma Q2 Results Review - India Branded Generic Growth Surprises; Upgrade To 'Buy': Systematix
India branded generics business recorded sales of Rs 42.7 billion, up 11% YoY and 2.9% QoQ, adds the brokerage.
Sun Pharma Q2 Results Preview: PAT likely to grow 11.5%; gross margin may improve
Led by growth in its domestic business, the specialty generic pharma company is expected to post good July-September quarter.
Sun Pharma Share Price Today Live Updates: Sun Pharma ends at Rs 1902.9
Discover the Sun Pharma Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...
Sun Pharma’s hair loss drug Leqselvi's launch remains in limbo
Leqselvi, projected to generate around $200 million in sales over the next three to four years for Sun Pharma, was slated for ...
ndtvprofit21m
Sun Pharma Q2 Results Review - Dolat Capital Sees Limited Upside, Maintains 'Reduce' Rating
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s ...
Sun Pharma Q2 profit up 27% on strong domestic, emerging mkts performance
Profit exceeded Bloomberg estimates by 3.6 per cent, while revenue fell by 0.43 per cent. Sun Pharma's agreement with ...
devdiscourse6h
Pharma & Food Giants Face Critical Scrutiny Amid Market Moves
Recent health industry updates reveal Sun Pharma's profit surge due to specialty drugs, Pfizer's strategic focus under ...